SLU-PP-332 Dosage: Metabolic Research Protocol

Read this first

Dosage and protocol figures on this page are reproduced only from the matching PeptideDosages.com protocol. The 3 ml table is arithmetic based on those source amounts and the listed vial sizes. Educational research only — not instructions or medical advice.

Dosage chart

The dosage amounts and schedules below come only from PeptideDosages.com. Syringe-unit figures are mathematical conversions of those source amounts using exactly 3 ml of bacteriostatic water. Educational reference only — not instructions or medical advice.

SLU-PP-332 · 5 mg Vial

SLU-PP-332 is dosed at 1.25 mg–2.5 mg daily via subcutaneous injection in educational protocols.

Evidence Base: Preclinical only—in vivo mouse studies with intraperitoneal dosing (25–50 mg/kg twice daily).
Murine dose range: 1250–2500 mcg daily (for a 25 g mouse), administered in two divided doses.

Murine-Equivalent Protocol

Phase	Daily Dose (mcg)	Per-Injection Dose (mcg)
Weeks 1–2	1250 mcg	625 mcg
Weeks 3–8	2500 mcg	1250 mcg

3 ml conversion

Select vial strength

5 mg + 3 ml = 1.67 mg/ml. Choose your vial strength to update the units below.

Source dose	U-100 syringe
1250 mcg	75 units
625 mcg	38 units
2500 mcg	150 units

Source chart on peptidedosages.com

Other metabolic compounds

SurvodutideDual glucagon receptor / GLP-1 receptor agonist Vitamin B12 (cyanocobalamin / methylcobalamin)Cobalamin vitamin AdipotidePro-apoptotic peptidomimetic targeting prohibitin in white adipose vasculature AICARAMP analogue and AMPK activator (small molecule, not a peptide)CagrilintideLong-acting amylin analogue (AMY1 class)GLP1 (semaglutide / Ozempic)GLP-1 receptor agonist

All research protocols

SLU-PP-332: research background

What the compound is

SLU-PP-332 is a synthetic compound developed to act as an 'agonist' for estrogen-related receptors (ERRs) alpha, beta, and gamma (ERRα, ERRβ, ERRγ) (PMID 37739806, PMID 36988910). An agonist is a substance that activates a receptor. ERRs are 'orphan nuclear receptors,' meaning their natural activating molecules were initially unknown (PMID 36988910, PMID 41421047). SLU-PP-332 is described as a 'pan-ERR agonist,' meaning it targets all three ERR subtypes, though it has the highest activating effect on ERRα (PMID 36988910). It has been characterized as an 'exercise mimetic' because it can trigger physiological processes similar to those induced by physical activity (PMID 41588687, PMID 41688415).

How it is thought to work

ERRs are crucial regulators of 'mitochondrial metabolism' and gene expression responsive to exercise (PMID 41850449). Mitochondria are often called the 'powerhouses' of cells. SLU-PP-332 works by activating these ERR receptors (PMID 37739806, PMID 36988910). This activation leads to an increase in mitochondrial function and cellular respiration in skeletal muscle cells (PMID 36988910, cells). It also transcriptionally activates a broad spectrum of genes involved in fatty acid metabolism and mitochondrial function (PMID 37961903, PMID 41688415, animals). In mouse hearts, this activation led to increased mitochondrial oxidative capacity and fatty acid use (PMID 37961903, animals). The activation of ERRα was found to be critical for improving exercise endurance in mice (PMID 36988910, animals).

What laboratory and animal studies report

In a skeletal muscle cell line, SLU-PP-332 increased mitochondrial function and cellular respiration (PMID 36988910, cells). When administered to mice, it increased type IIa oxidative skeletal muscle fibers and enhanced exercise endurance (PMID 36988910, animals). Studies in mice also showed that SLU-PP-332 administration mimicked exercise-induced benefits on whole-body metabolism, including increased energy expenditure and fatty acid oxidation (PMID 37739806, animals). This was accompanied by decreased fat mass accumulation, reduced obesity, and improved insulin sensitivity in mouse models of metabolic syndrome (PMID 37739806, animals). In mouse models of heart failure, SLU-PP-332 significantly improved ejection fraction and ameliorated fibrosis without affecting cardiac hypertrophy (PMID 37961903, animals). The compound also reversed age-related increases in albuminuria, podocyte loss, mitochondrial dysfunction, and inflammatory markers in aging mouse kidneys (PMID 37717940, animals).

Open questions and limitations

SLU-PP-332 lacks oral bioavailability, meaning it is not effectively absorbed when taken by mouth (PMID 41421047). While extensive in vitro metabolism studies have identified numerous metabolites of SLU-PP-332 using human liver fractions (PMID 41588687, PMID 41688415), further studies are necessary to fully understand the structures of these metabolites (PMID 41688415). The World Anti-Doping Agency (WADA) prohibits the use of exercise mimetics, and the identification of SLU-PP-332's metabolites is considered a critical step for doping control purposes (PMID 41588687, PMID 41688415).

Key terms explained

An 'agonist' is a substance that binds to and activates a receptor, causing a biological response (PMID 37739806). 'Estrogen-related receptors' (ERRs) are a group of nuclear receptors involved in regulating metabolism and exercise adaptations (PMID 36988910). 'Metabolic syndrome' is a cluster of conditions that increase the risk of heart disease, stroke, and type 2 diabetes (PMID 37739806). 'Mitochondrial dysfunction' refers to problems with mitochondria, the parts of cells that generate most of the chemical energy needed to power biochemical reactions (PMID 37717940). 'Oral bioavailability' describes the proportion of a drug that enters the circulation when introduced into the body orally and is able to have an active effect (PMID 41421047).

Studies cited in this section

A Synthetic ERR Agonist Alleviates Metabolic Syndrome. — The Journal of pharmacology and experimental therapeutics, 2024 (PMID 37739806)
Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function. — Circulation, 2024 (PMID 37961903)
Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. — ACS chemical biology, 2023 (PMID 36988910)
Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney. — The American journal of pathology, 2023 (PMID 37717940)
An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity. — The Journal of pharmacology and experimental therapeutics, 2026 (PMID 41421047)
Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling. — International journal of biological macromolecules, 2026 (PMID 41850449)
In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential. — Rapid communications in mass spectrometry : RCM, 2026 (PMID 41588687)
Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes. — Drug testing and analysis, 2026 (PMID 41688415)

Summarised from the PubMed abstracts listed above. Educational reference only — not medical advice or instructions.

Nearby in the protocol A–Z

Peptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.

SLU-PP-332 dosage protocol